Table 2.
Lung function and proportions with blood eosinophils (EOS) < 0.3, 0.3 ≤ EOS<0.4, and EOS≥0.4 × 109/L, respectively, by the use of inhaled corticosteroids (ICS) at follow-up.
| ICS use at follow-up |
p-valuea | |||
|---|---|---|---|---|
| ICS naive | ICS users | |||
| n = 502 | n = 390 | |||
| Blood eosinophils at follow-up | ||||
| EOS<0.3 | n (%) | 394 (78.5) | 255 (65.4) | |
| 0.3 ≤ EOS<0.4 | n (%) | 52 (10.4%) | 62 (15.9) | |
| EOS≥0.4 | n (%) | 56 (11.2) | 73 (18.7) | <0.001 |
| Lung function | ||||
| FEV1 % of predicted at baseline | mean (SD) | 91.0 (12.3) | 85.6 (14.9) | <0.001 |
| FEV1 % of predicted at follow-up | mean (SD) | 89.1 (14.9) | 84.4 (17.5) | <0.001 |
| Annual FEV1 decline in % of predicted | mean (SD) | −0.09 (0.55) | −0.05 (0.69) | 0.384 |
| Annual FEV1 decline in ml | mean (SD) | −28.2 (19.2) | −26.5 (23.7) | 0.239 |
a
chi-square p-value for difference in proportions or T-test p-value for difference in means between groups based on ICS use at follow-up. EOS = blood eosinophils at follow-up, ICS = Inhaled corticosteroids at follow-up. Bold values indicate statistical significance